Effect of synbiotic supplement on placental uterine blood flow in patients with polycystic ovary syndrome

The effect of synbiotic supplementation on placental uterine blood flow, lipid profile and glycemic index in pregnant women with polycystic ovary syndrome

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191104045328N17

Enrollment

Registered

2023-10-02

Start date

2023-10-22

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovary syndrome. Polycystic ovarian syndrome

Interventions

Intervention 1: Intervention group: In the intervention group, patients will take one supplement capsule of Synbiotic Lactofem from Zisttakhmir company daily from the 28th week of pregnancy until the

Eligibility

Sex/Gender

Female

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Pregnant mothers of 28 and 37 weeks of pregnancy with polycystic ovaries referred to Arak Taleghani Hospital. Age 18-50 years Consent to participate in the study

Exclusion criteria

Exclusion criteria: History of congenital disease History of chronic diseases such as diabetes, cancer, high blood pressure, liver or kidney failure, etc. History of intrauterine growth restriction or preeclampsia or pregnancy complications in previous pregnancies Having a special diet or taking anti-inflammatory and sugar-lowering supplements in the last 6 months

Design outcomes

Primary

Measure	Time frame
PI of the umbilical artery. Timepoint: in the 28th and 37th weeks of pregnancy. Method of measurement: Doppler ultrasound.;Baby's birth weight. Timepoint: at birth. Method of measurement: scales.;Apgar score. Timepoint: 1st and 5th minute of birth. Method of measurement: Apgar chart.;Gestational age at delivery. Timepoint: At the time of delivery. Method of measurement: time of birth.;PI uterine artery. Timepoint: in the 28th and 37th weeks of pregnancy. Method of measurement: Doppler ultrasound.;Preeclampsia. Timepoint: Monitoring during pregnancy. Method of measurement: Clinical trials and examinations.;Intrauterine growth restriction. Timepoint: Monitoring during pregnancy. Method of measurement: sonography.;Fasting blood glucose. Timepoint: 28th and 37th weeks of pregnancy. Method of measurement: Laboratory.;Oral glucose tolerance tests. Timepoint: 28th and 37th weeks of pregnancy. Method of measurement: Laboratory.;Homeostatic Model Assessment for Insulin Resistance. Timepoint: 28th and 37th weeks of pregnancy. Method of measurement: Laboratory.;Lipid profile. Timepoint: 28th and 37th weeks of pregnancy. Method of measurement: Laboratory.	—

Measure

Time frame

PI of the umbilical artery. Timepoint: in the 28th and 37th weeks of pregnancy. Method of measurement: Doppler ultrasound.;Baby's birth weight. Timepoint: at birth. Method of measurement: scales.;Apgar score. Timepoint: 1st and 5th minute of birth. Method of measurement: Apgar chart.;Gestational age at delivery. Timepoint: At the time of delivery. Method of measurement: time of birth.;PI uterine artery. Timepoint: in the 28th and 37th weeks of pregnancy. Method of measurement: Doppler ultrasound.;Preeclampsia. Timepoint: Monitoring during pregnancy. Method of measurement: Clinical trials and examinations.;Intrauterine growth restriction. Timepoint: Monitoring during pregnancy. Method of measurement: sonography.;Fasting blood glucose. Timepoint: 28th and 37th weeks of pregnancy. Method of measurement: Laboratory.;Oral glucose tolerance tests. Timepoint: 28th and 37th weeks of pregnancy. Method of measurement: Laboratory.;Homeostatic Model Assessment for Insulin Resistance. Timepoint: 28th and 37th weeks of pregnancy. Method of measurement: Laboratory.;Lipid profile. Timepoint: 28th and 37th weeks of pregnancy. Method of measurement: Laboratory.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Fatemeh Seidi

Arak University of Medical Sciences

fatemehseidi@arakmu.ac.ir+98 86 3222 2003

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026